Histotype Px® Colorectal
Clinical decision support
To optimize cancer treatment, we must understand how the disease will develop. The Histotype Px® Colorectal digital biomarker is able to predict the disease outcome for colorectal cancer patients and can guide personalized treatment decision for each patient and thereby avoiding over- and undertreatment
How was the Histotype Px® Colorectal biomarker developed?
Histotype Px® Colorectal* digital biomarker is the most advanced deep convolutional neural network algorithm for determining prognosis in colorectal cancer based on standard histology images. The colorectal algorithm is robust and based on solid ground truth and extensive training and testing with in total 4500 patient samples, 90 million image tiles, from +200 sites in 8 countries. The slides were prepared at several sites, scanned at two sites with two different scanners, ensuring that the test can be used in clinical practice.
*The early version of Histotype Px® Colorectal was named DoMore-V1-CRC (and misc. variations of this description) during development in the DoMore! Project. The CE-IVD certified product Histotype Px® Colorectal is an updated version.
AI and digital pathology will revolutionize the way we treat cancer
CEO and Co-Founder Torbjørn Furuseth presents the company and our leading digital biomarker Histotype Px® Colorectal at the LSX Nordic Congress 2023.
Technology
DoMore Diagnostics is a pioneer in utilizing artificial intelligence to increase the prognostic and predictive value of cancer tissue biopsies. The company’s AI-powered digital biomarker is based on extensive research at top universities with deep learning in histology image analysis. These new methods have resulted in fully automated histotyping that provide objective and precise prognostic information about patient outcomes. This novel histotyping can guide selection of therapy to avoid over- and undertreatment of cancer patients. It can also make cancer drug development more effective by ensuring more precise diagnosis and prognosis, which is the fundament for precision medicine.
Future Pipeline
DoMore Diagnostics is dedicated to expanding our potential and impact on improving cancer patients’ lives. We are actively pursuing further development and advancing our product portfolio for better outcome prediction and personalized cancer treatment.
Intellectual Property
DoMore Diagnostics has secured a global, exclusive license to the patents and patent applications covering the inventions.